237384-37-1

Basic information

• Product Name: methyl 4-[4-(2-methylphenyl)(1,3-thiazol-2-yl)]-5-methylthiothiophene-2-carboxylate
• Synonyms: methyl 4-[4-(2-methylphenyl)(1,3-thiazol-2-yl)]-5-methylthiothiophene-2-carboxylate
• CAS NO: 237384-37-1
• Molecular Weight: 361.51
• Mol File: 237384-37-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 4-[4-(2-methylphenyl)(1,3-thiazol-2-yl)]-5-methylthiothiophene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-[4-(2-methylphenyl)(1,3-thiazol-2-yl)]-5-methylthiothiophene-2-carboxylate(237384-37-1)
• EPA Substance Registry System: methyl 4-[4-(2-methylphenyl)(1,3-thiazol-2-yl)]-5-methylthiothiophene-2-carboxylate(237384-37-1)

Safety Data

• Hazardous Substances Data: 237384-37-1(Hazardous Substances Data)

Upstream product

• 175202-48-9 methyl 4‐cyano‐5‐(methylthio)thiophene‐2‐carboxylate 
• 51012-65-8 2-bromo-1-o-tolylethanone 
• 209056-81-5 methyl 4-(aminothioxomethyl)-5-methylthiothiophene-2-carboxylate 

Downstream Products

• 237381-43-0 4-[4-(2-methylphenyl)(1,3-thiazol-2-yl)]-5-methylthiothiophene-2-carboxamidine hydrochloride 

Relevant articles and documents

Compounds and compositons for treating C1s-mediated diseases and conditions

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, X, Y and Z are defined in the specification.

Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors

The present invention is directed to compounds of Formula I: wherein X is O, S or NR7and R1-R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.